- Home
- UTMD vs NKTR Comparison
UTMD vs NKTR Comparison
Compare UTMD & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTMD
- NKTR
- Stock Information
- Founded
- UTMD 1978
- NKTR 1990
- Country
- UTMD United States
- NKTR United States
- Employees
- UTMD N/A
- NKTR N/A
- Industry
- UTMD Medical/Dental Instruments
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- UTMD Health Care
- NKTR Health Care
- Exchange
- UTMD Nasdaq
- NKTR Nasdaq
- Market Cap
- UTMD N/A
- NKTR 160.4M
- IPO Year
- UTMD N/A
- NKTR 1994
- Fundamental
- Price
- UTMD $56.04
- NKTR $0.68
- Analyst Decision
- UTMD
- NKTR Strong Buy
- Analyst Count
- UTMD 0
- NKTR 5
- Target Price
- UTMD N/A
- NKTR $5.50
- AVG Volume (30 Days)
- UTMD 17.2K
- NKTR 1.5M
- Earning Date
- UTMD 04-24-2025
- NKTR 03-12-2025
- Dividend Yield
- UTMD 2.17%
- NKTR N/A
- EPS Growth
- UTMD N/A
- NKTR N/A
- EPS
- UTMD 3.96
- NKTR N/A
- Revenue
- UTMD $40,903,000.00
- NKTR $98,427,000.00
- Revenue This Year
- UTMD N/A
- NKTR N/A
- Revenue Next Year
- UTMD N/A
- NKTR N/A
- P/E Ratio
- UTMD $14.18
- NKTR N/A
- Revenue Growth
- UTMD N/A
- NKTR 9.21
- 52 Week Low
- UTMD $55.81
- NKTR $0.65
- 52 Week High
- UTMD $77.33
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- UTMD 24.89
- NKTR 31.49
- Support Level
- UTMD $56.67
- NKTR $0.84
- Resistance Level
- UTMD $57.61
- NKTR $0.92
- Average True Range (ATR)
- UTMD 0.91
- NKTR 0.07
- MACD
- UTMD -0.05
- NKTR -0.02
- Stochastic Oscillator
- UTMD 7.87
- NKTR 3.95
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.